XenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on the WHITE Proxy Card

  XenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on
  the WHITE Proxy Card

Business Wire

SANTA CLARA, Calif. -- June 6, 2014

XenoPort, Inc.(Nasdaq:XNPT) today reminded stockholders to vote at the
Company’s upcoming Annual Meeting of Stockholders on June 11, 2014.

Time is short and stockholders are encouraged to vote the WHITE proxy card
today. XenoPort urges stockholders not to return any proxy card sent to them
by Clinton Relational Opportunity Master Fund, L.P.and its affiliates
(Clinton). Even if stockholders have already voted using the gold proxy card,
they have the right to change their vote simply by executing and submitting
the WHITE proxy card in support of XenoPort’s director nominees. Only the
last-dated proxy card will count.

Stockholders can vote by telephone or Internet according to the instructions
on the WHITE proxy card.Voting by telephone or Internet is the best way to
ensure that votes will be counted.

Two independent proxy advisory firms, Institutional Shareholder Services (ISS)
and Egan-Jones Proxy Services (Egan-Jones), have recommended that XenoPort
stockholders vote on the WHITE proxy card “FOR ALL” of XenoPort’s director
nominees: Ronald W. Barrett, Ph.D.,Jeryl L. HillemanandWendell Wierenga,
Ph.D.

XenoPort also urges stockholders to vote "FOR" the approval of theXenoPort,
Inc.2014 Equity Incentive Plan, vote "FOR" the approval, on an advisory
basis, of the compensation of XenoPort's named executive officers, and vote
"FOR" the ratification of the selection by the audit committee of the Board of
Directors ofErnst & Young LLPas XenoPort's independent registered public
accounting firm for the fiscal year endingDecember 31, 2014. In addition, the
XenoPort Board urges stockholders to vote "FOR" Proposals 9 through 14 and
"AGAINST" Clinton Proposals 5 through 8.

     If you have any questions, require assistance with voting your WHITE
 proxy card or need additional copies of the proxy materials, please contact:

                           MACKENZIE PARTNERS, INC.

                              105 Madison Avenue
                              New York, NY 10016

                         proxy@mackenziepartners.com

                        (212) 929-5500 (Call Collect)
                                      Or
                           TOLL-FREE (800) 322-2885

Important Additional Information and Where to Find It

XenoPort, Inc., its directors and certain of its executive officers may be
deemed to be participants in the solicitation of proxies from stockholders in
connection with XenoPort's 2014 Annual Meeting of Stockholders.XenoPorthas
filed with theSECand provided to its stockholders a definitive proxy
statement and aWHITEproxy card in connection with such solicitation.
XENOPORT STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT
(INCLUDING ANY AMENDMENTS AND SUPPLEMENTS) AND THE ACCOMPANYINGWHITEPROXY
CARD, AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE, BECAUSE
THEY CONTAIN IMPORTANT INFORMATION.

Information regarding the names of XenoPort's directors and executive officers
and their respective interests inXenoPortby security holdings or otherwise
is set forth in XenoPort's definitive proxy statement for the 2014 Annual
Meeting of Stockholders, filed with theSEConApril 22, 2014, including
Appendix B thereto.

The definitive proxy statement (and amendments or supplements thereto) and the
accompanyingWHITEproxy card, and any other relevant documents and other
material filed byXenoPortwith theSEC, are or will be available for no
charge at the SEC's website atwww.sec.govand at XenoPort's investor
relations website athttp://investor.xenoport.com/index.cfm. Copies may also
be obtained free of charge by contacting XenoPortInvestor Relations by mail
at3410 Central Expressway,Santa Clara, California95051 or by telephone at
(408) 616-7200.

AboutXenoPort

XenoPort, Inc.is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders.XenoPortis currently
commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets
inthe United Statesand developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for psoriasis and/or relapsing
forms of multiple sclerosis. REGNITE^® (gabapentin enacarbil) Extended-Release
Tablets is being marketed inJapanby Astellas Pharma Inc. XenoPort'spipeline
of product candidates also includes a potential treatment for patients with
Parkinson's disease. To learn more aboutXenoPort, please visit the Web site
atwww.XenoPort.com.

HORIZANT, REGNITE andXENOPORTare registered trademarks ofXenoPort, Inc.

XNPT2G

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.